Clinical trial · Observational
Neutrophils to Lymphocytes Ratio in Predicting the Response to BCG in Non-muscle Invasive Bladder Cancer
Preoperative Neutrophils to Lymphocytes Ratio in Predicting the Response to BCG in Non-muscle Invasive Bladder Cancer
NCT05946369CI-TRIAL-00068075completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
There is a relation between inflammatory cells and the prognosis of tumors (cancer colon, renal, liver, and urinary bladder). In this study, the investigators will link the Neutrophils to Lymphocytes ratio to the response to intravesical BCG therapy post trans-urethral resection of urinary bladder tumors for the non-invasive urinary bladder tumors.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| BCG | — | UNRESOLVED | — |
| Non-Muscle Invasive Bladder Urothelial Carcinoma | Non-Muscle Invasive Bladder Urothelial Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Trans Urethral Resection of a Bladder Tumor | — | UNRESOLVED | — |
| Urinary Bladder Cancer | Malignant Bladder Neoplasm | ALIAS | 0.90 |
| Urinary Bladder Neoplasm | Bladder Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Neutrophil to lymphocyte ratio | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Neutrophil to lymphocyte ratio less than 3
- description
- Patients are classified into 2 groups according to NLR \< or ≥ 3 and follow up the 2 groups for recurrence or regression of bladder urothelial tumor and documentation of BCG failure
- interventionNames
- Diagnostic Test: Neutrophil to lymphocyte ratio
- label
- Neutrophil to lymphocyte ration more than or equal 3
- description
- Patients are classified into 2 groups according to NLR \< or ≥ 3 and follow up the 2 groups for recurrence or regression of bladder urothelial tumor and documentation of BCG failure
- interventionNames
- Diagnostic Test: Neutrophil to lymphocyte ratio
Primary outcomes (1)
- measure
- BCG failure
- timeFrame
- 3 years following tumor resection and BCG instillation
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Patients with non-muscle invasive urothelial tumor of the urinary bladder Exclusion Criteria: 1. Concomitant malignancy. 2. Hematological disorders. 3. History of radiation or chemotherapy. 4. Concomitant infection or chronic inflammatory diseases. 5. Missing preoperative differential blood cell count. 6. Patients with low grade non muscle invasive Urinary baldder tumors. 7. Patients missing BCG after biopsy revealing NMIBC. 8. patients with non-compliance to BCG doses or the scheduled follow up.
References
Publications (0)
Data not yet available
No reference posted for this study.